Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for S100P drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | S100P Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Active homodimer conformation. |
View S100P Products |
| Gene Delivery | S100P Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. |
View S100P Products |
| Benchmark Ab | Anti-S100P Recombinant Antibody Recombinant positive control for validation assays. |
View S100P Products |
| Validator | S100P siRNA Set For target knockdown and specificity verification. |
View S100P Products |
| Related Target A | AGER (RAGE) Primary extracellular receptor for S100P, driving oncogenic signaling and metastasis. |
View AGER Products |
| Related Target B | S100A4 S100 family member associated with metastatic progression and epithelial-mesenchymal transition. |
View S100A4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| S100 Family Cross-reactivity Screening | Highly purified S100 family panel (S100A4, S100A6, S100A9) sequence verified by mass spectrometry. |
| Calcium-Dependent Conformation Control | Recombinant S100P proteins batch-tested for structural integrity under physiological calcium concentrations. |
| Lack of Controls | Clinical-grade benchmark antibodies included in the portfolio. |
| False Positives in Binding Assays | Validated siRNA sets included for specific target knockdown validation. |
Live S100P R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for S100P therapeutics is intensifying, with major players shifting focus from traditional small molecules to targeted monoclonal antibodies and drug conjugates. As first-generation therapies reach the clinic, the next wave of R&D is targeting the disruption of the extracellular S100P-RAGE signaling axis to suppress pancreatic and colorectal cancer metastasis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Academic Medical Centers, Biotech Startups | Pancreatic Ductal Adenocarcinoma, Breast Cancer | Ligand-receptor blocking assays (Requires high-purity S100P and AGER/RAGE proteins) |
| Small Molecule Inhibitor | Pharmaceutical Research Institutes | Metastatic Colorectal Cancer, Prostate Cancer | High-throughput screening (Requires stable S100P protein and calcium-binding assays) |
| siRNA / Therapeutics | RNAi Therapeutics Developers | Refractory Solid Tumors | In vitro knockdown validation (Requires validated siRNA tools and stable cell lines via lentivirus) |